IL-13 production from mouse splenocytes cultured with mHis6IL-25 was assessed. Mouse splenoyctes were treated with increasing concentrations of mHis6IL-25 for 72 hr. Cell supernatants were then harvested and assayed for IL-13 by ELISA, and the OD450 was determined.
GRO α production from HT-29 cells cultured with mHis6IL-25 was assessed. HT-29 cells were treated with increasing concentrations of mHis6IL-25 for 24 hr. Cell supernatants were then harvested and assayed for GRO α by ELISA, and the OD450 was determined.
The purity of recombinant mHis6IL-25 was determined by SDS-PAGE of 6 µg reduced (+) and nonreduced (-) recombinant mHis6IL-25 and staining overnight with Coomassie Blue.
With carrier: Lyophilized from a 0.22 μm filtered solution of mHis6IL-25 in 20 mM Tris, pH 7.2 containing 20 μg BSA per 1 μg mHis6IL-25. Carrier free: Lyophilized from a 0.22 μm filtered solution of mHis6IL-25 in 20 mM Tris, pH 7.2.
Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles. Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
>97% as determined by SDS-PAGE of 6 μg reduced (+) and nonreduced (-) recombinant mHis6IL-25. All lots are greater than 97% pure.
Recombinant N-terminally His6-tagged mIL-25 has a calculated MW of 20,051 Da. DTT-reduced protein migrates as a 24-31 kDa polypeptide. The nonreduced cystine-linked homodimer migrates as a 46-50 kDa protein. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino terminus of recombinant mHis6IL-25 was verified by amino acid sequencing.
Recombinant mouse His6IL-25 (mHis6IL-25) Val17-Ala169 (Accession #NP_542767) was expressed in human 293 cells at Cell Signaling Technology.
IL-25, also known as IL-17E, is a member of the IL-17 superfamily of cytokines. IL-25 is expressed in epithelial cells, CD4+ T cells, mast cells, and eosinophils (1). Many cell types are responsive to IL-25, including T cells, macrophages, and epithelial cells (1). The receptor for IL-25 consists of a heterodimer of IL-17RA and IL-17RB (1,2). IL-25 promotes Th2 type immune responses by induction of IL-5, IL-4, and IL-13 and may contribute to allergic inflammation and asthma (1-3). IL-25 has also been shown in research to promote Th9 cell activation and induce apoptosis in breast cancer cells (4,5).
Explore pathways + proteins related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.